Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celiac Ganglion Block for Dysautonomia-Related Bowel Dysmotility
NCT04121338Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Dec 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liposomal bupivacaine in dysautonomia, sponsored by Johns Hopkins University. Primary endpoints: Amount of solid food intake by mouth per day at 2 days and Change in abdominal pain at 2 days. Started Dec 2019; status: completed.
02
Drugs
liposomal bupivacaine
03
Conditions
dysautonomia
Beyond the preview
Go deeper on NCT04121338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121338.